Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Implantica announces that RefluxStop™ results were presented at the DDW Conference in Chicago

Implantica AG (publ), a medtech company at the forefront of bringing advanced technology into the body, announces that Dr. med. Zehetner, Prof. (USC) from Switzerland, presented Klinik Beau-Site’s RefluxStop™ results at Digestive Disease Week (DDW) 6-9 May, in Chicago, U.S., the world’s premier meeting for gastrointestinal professionalsDr. med. Jörg Zehetner, Prof. (USC), surgeon at the Hirslanden Klinik Beau-Site Bern, Switzerland, highlighted the unique advantages of the RefluxStop™ therapy in the reflux patient population that have Ineffective Esophageal Motility (IEM), a disorder that

KLAR Partners boosts Enerim’s future growth prospects through a strategic divestment of its Wholesale Markets business to allow enhanced focus on its market-leading SaaS solutions

After a successful carve-out and reorganisation of the business, funds advised by KLAR Partners Limited (“KLAR Partners” or “KLAR”) are supporting Enerim Oy (“Enerim” or the “Company”) on the next step of its growth journey. By divesting its Wholesale Markets business, the company can concentrate on streamlining its software offering while consolidating its leading position as a supplier of SaaS solutions to utility companies in northern Europe.With its End User Markets business, Enerim has established itself as a market-leading provider of mission-critical SaaS solutions that automate

Proact subsidiary Conoa partners with Isovalent

Proact and its subsidiary Conoa – a Kubernetes, cloud native and container technology consulting firm has entered into a partnership with Isovalent to further expand its portfolio around visibility, control, performance, and security of customers’ container environments.As the first Isovalent  partner in Sweden, Conoa is authorised to resell and implement Isovalent Cilium Enterprise – an innovative technology that offers efficient and scalable network connectivity and security for Kubernetes-based container environments. Conoa can support customers across all Proact

Thomas Hietto appointed new Business Area President for Sweco Finland

Thomas Hietto takes up the role as the new Business Area President for Sweco Finland and joins Sweco AB’s Executive Team effective 1 June 2023.For the greater part of his career, Thomas Hietto has worked for the Kone Corporation in several senior positions and in different markets around the world. He has also been Deputy CEO of Caverion Corporation. Thomas Hietto holds an MSc in Industrial Management from Helsinki University of Technology (Aalto University), Finland as well as an MSc in Management from Stanford Graduate School of Business, USA.  Thomas Hietto will succeed Markku Varis

Read original

Phi Ta Khon, Thai Ghost Festival 2023 scheduled from 23-25 June

The unique tradition of Bun Luang and Phi Ta Khon Festival – also known as the Ghost Festival – will be held from 23 – 25 June 2023, in Dan Sai district of the Northeastern province of Loei.   The most recognized feature of the three-day festival is the grand Phi Ta Khon parade of locals who dance, and strike poses while wearing huge masks creatively made from carved coconut-tree trunks, topped with wicker sticky-rice steamers that make them appear taller and more grotesque. But when you look beyond the mask you see how the Phi Ta Khon celebrations are all about paying homage

HC Andersen Capital Events 16/05: Meet the top management in ExpreS2ion Biotechnologies & Penneo

HC Andersen Capital is hosting digital events where you can meet and ask questions directly to the top management. It is free for all to attend.ExpreS2ion Biotechnologies – Presentation of Q1 2023ExpreS2ion Biotechnologies is expected to release its Q1 2023 results on 16 May 2023. Later the same day at 11:00, ExpreS2ion Biotechnologies’ CEO Bent Frandsen and CFO Keith Alexander will present the results and latest achievements followed by a Q&A session in a virtual live event.  Besides the quarterly results, we expect attention, among others, could be directed to the outcome of the

Lagercrantz Year-end Report 2022/23

FOURTH QUARTER (1 JanuarY – 31 MarCH 2023) · Net revenue increased by 30% to MSEK 2,040 (1,575),of which organic growth amounted to 9%. · Operating profit (EBITA) increased by 29% to MSEK 343 (265),equivalent to an EBITA margin of 16.8% (16.8). · Profit after financial items (EBT) increased by 27% to MSEK 272 (214). · Cash flow from operating activities amounted to MSEK 418 (168). · Profit after taxes increased by 26% to MSEK 213 (169).   the financial year (1 APRIL 2022 – 31 march 2023) · Net revenue increased by 32% to MSEK 7,246 (5,482),of which organic

Penneo achieves 27% year-on-year ARR growth in Q1-2023

Company Announcement No. 22-2023Copenhagen, 16 May 2023Quarterly financial report for the period 1 January 2023 - 31 March 2023Q1-2023 performance highlights · ARR increased by 3.3M DKK to 74.2M DKK in Q1-2023, corresponding to 27% year-on-year (YoY) growth at the end of the quarter · ARR increase from Newbizz amounted to 2.0M DKK compared to 1.9M DKK in Q1-2022 · ARR increase from uplift amounted to 2.0M DKK compared to 1.6M DKK in Q1-2022  · ARR lost to churn amounted to 0.6M DKK compared to 0.4M DKK in Q1-2022 · ARR from foreign markets increased by 0.9M DKK compared

Investment Outlook: Falling inflation will provide support during slump

China’s economy is gearing up as the rest of the world slows down into a brief, shallow recession in which corporate earnings will hold up well. The investor community is restrained and cautiously positioned, while the corporate sector is thriving and in good shape. Our main economic scenario foresees a slowdown in 2023 and an acceleration during 2024. We support a neutral allocation at the asset class level, combined with good risk diversification, since volatility is likely to persist. “In this environment of positive and negative forces, since early autumn 2022 we have advocated a

Interim report January - March 2023

A robust core business – and strategic advances January 1 - March 31, 2023 · Net sales increased 26 percent to SEK 3,973 M (3,155). Adjusted for the acquisition of Koivunen, net sales increased 11 percent. Organic growth was 6 percent. · Net sales were positively impacted by 2 percent due to currency effects. · EBIT amounted to SEK 200 M (190) and the EBIT margin was 4.9 percent (5.9). EBIT was not impacted by any items affecting comparability during the quarter nor during the year-earlier period. · Adjusted EBIT amounted to SEK 227 M (225) and the adjusted EBIT margin was

SLP extends lease agreement with Veolia for 3,950 sqm and increases rent due to solar cell investment

SLP has extended a lease with Veolia by three years regarding the property Eskilstorp 14:97 in Malmö. Veolia has been a tenant since 2005 and rents the entire building of a total of 3,950 square meters. The existing lease, which expires on October 31, 2024, is thus extended by three years to October 31, 2027, at the same time an extended lease has been agreed to build a solar cell system on the property. The new annual rent is fully index regulated. Current lease is index regulated by 60%."It is gratifying that we have signed an extended agreement with Veolia while investing in

Announcement of Annual General Meeting in Akobo Minerals AB (publ)

The shareholders of Akobo Minerals AB (publ), company registration no 559148-1253 (the “Company”), are hereby invited to participate in the Annual General Meeting (“AGM”) to be held on June 19, 2023 at 10.00 am at the Company’s office at Södra Allégatan 13, Göteborg, Sweden. Participation Shareholders that wish to participate in the procedures at the AGM must: · on June 9, 2023, be recorded as shareholders in the share register kept by Euroclear Sweden AB (temporary registration for shareholders registered at the Norwegian CSD, Euronext Securities Oslo (formerly VPS) is made by

Neogap enrols first patient in Phase I/II clinical trial of personalised immunotherapy for colorectal cancer

Swedish biotechnology company Neogap Therapeutics, specialising in personalised immunotherapy for cancer treatment, has announced the successful enrolment of its first patient in a Phase I/II clinical trial targeting advanced colorectal cancer.Neogap has included the first patient in their first-in-human trial with the cell therapy product pTTL (personalised Tumour Trained Lymphocytes). Production of personalised EpiTCer[®] beads for the patient has been initiated. These beads play a crucial role in the pTTL therapy by facilitating the training of the T cells to recognise neoantigens and

Nordhealth AS: Q1/2023 results presentation

Please find attached the presentation of Nordhealth AS Q1/2023 results.The results will be presented in a live webcast and subsequent Q&A session with CEO Charles MacBain and CFO Mari Orttenvuori on the 16th of May 2023 at 13:00 CET. Please use the following link to attend: https://us02web.zoom.us/j/88442219363  The presentation will be recorded and made available on www.nordhealth.com For further information, please contact: Charles MacBain, CEO charles.macbain@nordhealth.com +44 75 3903 2200 Mari Orttenvuori, CFO mari.orttenvuori@nordhealth.com +358 46 8765 233

Synsam Group’s Q1 report 2023

Stronger organic growth (17.5 percent) and improved EBITDA margin compared with Q4 2022 - ”Cost programme starting to deliver according to plan”1 January - 31 March 2023 · Net sales amounted to SEK 1,411 million (1,186), up 19.0 percent. Organic growth totalled 17.5 percent (12.3) · Net sales from spectacles subscriptions increased 27 percent (18) · The gross margin was 76.6 percent (79.3) · EBITDA[[1]] rose to SEK 318 million (293) and the EBITDA margin was 22.3 percent (24.4) · EBITA amounted to SEK 171 million (178) and the EBITA margin was 12.0 percent (14.7) · EBIT

Thunderful Group Interim Report January–March 2023

A solid first quarter in a year with several exciting game releasesFirst quarter January–March 2023 · Net revenue increased 1.7 percent to 555.4 MSEK (546.0). · Operating profit (EBIT) increased 217.5 percent to 19.2 MSEK (6.0), corresponding to an operating margin of 3.1 percent (1.0). · Adjusted EBITDA increased 63.1 percent to 72.6 MSEK (44.5), corresponding to an adjusted EBITDA margin of 11.9 percent (7.3). · Adjusted EBITA increased 86.5 percent to 52.5 MSEK (28.1), corresponding to an adjusted EBITA margin of 8.6 percent (4.6). · Profit for the quarter amounted to 13.

Notice to Attend the Annual General Meeting in Scandinavian Real Heart AB

Press Release, 16 May 2023 The shareholders in Scandinavian Real Heart AB, reg. no. 556729–5588 (the "Company"), are hereby invited to the Annual General Meeting on Wednesday, 14 June 2023 at 15.00 at Best Western Plus Hotel Plaza, Kopparbergsvägen 10, 722 13 Västerås. Registration for the Meeting begins at 14:30.Right to participate in the Meeting, etc. Shareholders who wish to participate in the Meeting shall · be recorded in the share register kept by Euroclear Sweden AB no later than Monday, 5 June 2023, and · notify the Company their intention to participate no later than

Change in the YIT Management Team: Jennie Stenbom appointed EVP, Human Resources at YIT

YIT Corporation Stock Exchange Release 16 May 2023 at 8:15 a.m.Change in the YIT Management Team: Jennie Stenbom appointed EVP, Human Resources at YIT YIT Corporation has appointed Jennie Stenbom (M. Ed., eMBA) as Executive Vice President, Human Resources and member of the Group Management Team. She will start in her position in November 2023, at the latest. Tanja Kauhajärvi, Vice President, Employment Relations and Services, has been appointed as interim EVP of HR and member of the Management Team, starting on 16 May 2023. YIT’s current EVP, Human Resources Katja Ahlstedt has decided to

Flex LNG – Key information relating to the cash dividend to by paid by Flex LNG for the first quarter 2023

May 16, 2023Hamilton, Bermuda Key information relating to the cash dividend to be paid by Flex LNG Ltd. (Ticker: FLNG) for the first quarter 2023. Note to shareholders registered in Euronext VPS, the Norwegian Central Security Depository:Due to implementation of the Central Securities Depository Regulation (CSDR) in Norway, please note the information on the payment date to the shares registered in Euronext VPS below. Dividend amount: $0.75Declared currency: USD. Dividends payable to shares registered with Euronext VPS will be distributed in NOK.Last day including right:

Flex LNG – First Quarter 2023 Earnings Release

May 16, 2023Hamilton, Bermuda Flex LNG Ltd. (“Flex LNG” or the “Company”) today announced its unaudited financial results for the three months ended March 31, 2023. Highlights: *        Vessel operating revenues of $92.5 million for the first quarter 2023, compared to $97.9 million for the fourth quarter 2022.*        Net income of $16.5 million and basic earnings per share of $0.31 for the first quarter 2023, compared to net income of $41.4 million and basic earnings per share of $0.78 for the fourth quarter 2022.*        Average Time Charter Equivalent[1] (“TCE”) rate of

Atrium Ljungberg extends its contract with Ericsson in Lindholmen in Gothenburg

Atrium Ljungberg has extended its lease contract with Ericsson in Gothenburg, comprising more than 37,000 m[2] in Lindholmen. The two companies are going to work together to enhance their sustainability and energy conservation measures.Ericsson has been a tenant ever since Atrium Ljungberg acquired the property in Lindholmen in 2017. There are currently 2,400 people working in this property, which has 37,000 m[2] of offices and development spaces. Ericsson has now decided to extend its lease contract and will therefore remain an integral part of Lindholmen for the next four years. “We

Interim Report Q1, 2023

Strong eGFR Data from Positive NefIgArd Phase 3 Trial Readout“In March we announced that the global NefIgArd Phase 3 trial successfully met its primary endpoint, estimated glomerular filtration rate (eGFR), with a p value < 0.0001. Achieving this clinically relevant endpoint of kidney filtration capability represents a crowning achievement after well over a decade of pioneering work in IgA nephropathy. Nefecon, commercially available in the US and Europe under the brand name TARPEYO[®] and Kinpeygo[®] respectively, seems to be disease modifying, having shown both immediate and enduring

Webstep ASA: First quarter results 2023

Oslo, 16 May 2023: Webstep ASA reports revenues of NOK 277.2 million (NOK 233.0 million) and EBIT of NOK 25.2 million (NOK 23.9 million) for the first quarter. The EBIT margin in the quarter was 9.1 per cent (10.3 per cent). Net profit for the first quarter was NOK 18.8 million (NOK 17.8 million).Webstep had 557 employees at the end of first quarter, an increase of 65 employees compared to corresponding quarter last year.  – As we leave the first quarter behind, we can report robust revenue growth, stable EBIT and a growing Webstep workforce. Our consultants are considered key in

There are no items matching the current filter
There are no more items matching the current filter
Back to top